ImCheck Therapeutics: Funding, Investors & Team (Sep 2026)
ImCheck Therapeutics is an engineer of immuno-modulatory antibodies intended for the therapy of malignant growth and other insusceptible related infections. The organization's administrations are taken part in the revelation and advancement of immunomodulators for treating bosom disease, gastric, ovarian malignant growth cells and other strong cancers.
ImCheck Therapeutics has raised $100M across 1 funding round on record, the most recent a Series C of $100M announced in Jun 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ImCheck Therapeutics Company Profile and Key Stats
Latest funding round on record: Jun 2022.
ImCheck Therapeutics Funding Rounds
ImCheck Therapeutics Founders and Leadership Team
Contact details for the ImCheck Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →ImCheck Therapeutics Funding Compared to Other Biotechnology Startups
ImCheck Therapeutics' latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ImCheck Therapeutics in Biotechnology and Marseille
Companies Similar to ImCheck Therapeutics
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
ImCheck Therapeutics Funding FAQs
What does ImCheck Therapeutics do?
ImCheck Therapeutics is an engineer of immuno-modulatory antibodies intended for the therapy of malignant growth and other insusceptible related infections. The organization's administrations are taken part in the revelation and advancement of immunomodulators for treating bosom disease, gastric, ovarian malignant growth cells and other strong cancers.
How much funding has ImCheck Therapeutics raised?
ImCheck Therapeutics has raised $100M across 1 round on record. The most recent is a Series C of $100M announced in Jun 2022.
When did ImCheck Therapeutics last raise funding?
ImCheck Therapeutics' most recent funding round on record is a Series C of $100M, announced in Jun 2022.
Who founded ImCheck Therapeutics?
FundedIQ lists Alem Truneh (Founder) at ImCheck Therapeutics.
Where is ImCheck Therapeutics headquartered?
ImCheck Therapeutics is based in Marseille, Provence-Alpes-Cote D'azur, France.
How many employees does ImCheck Therapeutics have?
ImCheck Therapeutics is in the 11-50 employee band.
How does ImCheck Therapeutics' funding compare to other Biotechnology startups?
ImCheck Therapeutics' latest round of $100M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's ImCheck Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ImCheck Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.